MCID: AMP007
MIFTS: 40

Amphetamine Abuse

Categories: Mental diseases

Aliases & Classifications for Amphetamine Abuse

MalaCards integrated aliases for Amphetamine Abuse:

Name: Amphetamine Abuse 12 54 15
Amphetamine-Related Disorders 43

Classifications:



External Ids:

Disease Ontology 12 DOID:670
ICD9CM 34 305.7
MeSH 43 D019969
UMLS 71 C0154536

Summaries for Amphetamine Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of amphetamines despite negative consequences.

MalaCards based summary : Amphetamine Abuse, also known as amphetamine-related disorders, is related to cocaine abuse and substance abuse. An important gene associated with Amphetamine Abuse is SLC6A3 (Solute Carrier Family 6 Member 3), and among its related pathways/superpathways are Circadian entrainment and NRF2 pathway. The drugs Risperidone and Antipsychotic Agents have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex, and related phenotypes are behavior/neurological and growth/size/body region

Related Diseases for Amphetamine Abuse

Diseases related to Amphetamine Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 cocaine abuse 29.9 SLC6A4 SLC6A3 SLC6A2 SLC18A2
2 substance abuse 29.3 SLC6A4 SLC6A3 HTR1B DRD5 DRD4 CNR1
3 attention deficit-hyperactivity disorder 28.7 SLC6A4 SLC6A3 SLC6A2 SLC18A2 HTR1B DRD5
4 alcohol dependence 28.1 SLC6A4 SLC6A3 SLC6A2 SLC18A2 HTR1B DRD5
5 alcoholic psychosis 10.3 SLC6A4 SLC6A3
6 inhibited male orgasm 10.3 SLC6A4 SLC6A3
7 vasculitis 10.2
8 toxic encephalopathy 10.2 SLC6A4 SLC6A3 SLC18A2
9 generalized anxiety disorder 10.2 SLC6A4 SLC6A3 SLC6A2
10 idiopathic corneal edema 10.2 DRD5 DRD4
11 myocardial infarction 10.1
12 acute myocardial infarction 10.1
13 psychosexual disorder 10.1 SLC6A4 HTR1B
14 premature ejaculation 10.1 SLC6A4 SLC6A3 HTR1B
15 periodic limb movement disorder 10.1 DRD5 DRD4
16 separation anxiety disorder 10.1 SLC6A4 SLC6A3 DRD4
17 borderline personality disorder 10.1 SLC6A4 SLC6A3 HTR1B
18 drug dependence 10.1 SLC6A4 SLC6A3 CNR1
19 oculogyric crisis 10.1 DRD5 DRD4
20 heroin dependence 10.1 SLC6A4 SLC6A3 DRD4
21 opiate dependence 10.1 SLC6A4 SLC6A3 DRD4
22 lingual-facial-buccal dyskinesia 10.1 DRD5 DRD4
23 eating disorder 10.0 SLC6A4 SLC6A3 CNR1
24 atrial standstill 1 10.0
25 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 10.0
26 arteriovenous malformation 10.0
27 migraine with aura 10.0 SLC6A4 SLC6A3 HTR1B
28 paranoid schizophrenia 10.0 SLC6A4 DRD5 CNR1
29 paroxysmal dystonia 10.0 SLC6A3 PVALB
30 mixed cerebral palsy 10.0 SLC6A3 DRD5 DRD4
31 chronic tic disorder 10.0 DRD5 DRD4
32 delusional disorder 10.0 SLC6A3 DRD5 DRD4
33 alcohol use disorder 10.0 SLC6A4 SLC6A3 HTR1B
34 choreatic disease 10.0 SLC18A2 DRD5 DRD4
35 retrograde amnesia 10.0 SLC6A4 ARC
36 bruxism 10.0 SLC6A4 DRD5 DRD4
37 migraine without aura 10.0 SLC6A4 DRD5 DRD4
38 burning mouth syndrome 9.9 SLC6A4 CNR1
39 cannabis abuse 9.9 DRD4 CNR1
40 schizophreniform disorder 9.9 DRD5 DRD4 CNR1
41 schizoaffective disorder 9.9 SLC6A4 DRD4 CNR1
42 cardiac conduction defect 9.9
43 triiodothyronine receptor auxiliary protein 9.9
44 immune deficiency disease 9.9
45 ventricular fibrillation, paroxysmal familial, 1 9.9
46 bacterial sepsis 9.9
47 aphasia 9.9
48 pain agnosia 9.9
49 cardiac arrest 9.9
50 thrombosis 9.9

Graphical network of the top 20 diseases related to Amphetamine Abuse:



Diseases related to Amphetamine Abuse

Symptoms & Phenotypes for Amphetamine Abuse

MGI Mouse Phenotypes related to Amphetamine Abuse:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 ARC CNR1 CREB5 DHRS3 DRD4 DRD5
2 growth/size/body region MP:0005378 10.06 ARC CNR1 CREB5 DHRS3 HTR1B PRKCH
3 mortality/aging MP:0010768 9.97 ARC CNR1 CREB5 DHRS3 DRD5 HTR1B
4 homeostasis/metabolism MP:0005376 9.96 CNR1 CREB5 DHRS3 DRD4 PRKCH SLC18A2
5 nervous system MP:0003631 9.73 ARC CNR1 DHRS3 DRD4 DRD5 PRKCH
6 taste/olfaction MP:0005394 8.8 CNR1 SLC18A2 SLC6A3

Drugs & Therapeutics for Amphetamine Abuse

Drugs for Amphetamine Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 111)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
2 Antipsychotic Agents Phase 4
3 Dopamine Antagonists Phase 4
4 Anesthetics, Local Phase 4
5 Vasoconstrictor Agents Phase 4
6 Anesthetics Phase 4
7 Quetiapine Fumarate Phase 4 111974-72-2
8
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
9
Amphetamine Approved, Illicit, Investigational Phase 3 300-62-9 5826 3007
10
Mirtazapine Approved Phase 3 85650-52-8, 61337-67-5 4205
11
Histamine Approved, Investigational Phase 3 51-45-6 774
12
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
13
Ethanol Approved Phase 3 64-17-5 702
14
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
15 Sympathomimetics Phase 3
16 Adrenergic Agents Phase 3
17 Central Nervous System Stimulants Phase 3
18 Neurotransmitter Agents Phase 3
19 Dopamine Agents Phase 3
20 Autonomic Agents Phase 3
21 Antidepressive Agents Phase 3
22 Dopamine Uptake Inhibitors Phase 3
23 Central Nervous System Depressants Phase 3
24 Tranquilizing Agents Phase 3
25 Dopamine D2 Receptor Antagonists Phase 3
26 Psychotropic Drugs Phase 3
27 Serotonin 5-HT2 Receptor Antagonists Phase 3
28 Serotonin Antagonists Phase 3
29 Serotonin Agents Phase 3
30 Anti-Anxiety Agents Phase 3
31 Adrenergic alpha-Antagonists Phase 3
32 Adrenergic Antagonists Phase 3
33 Histamine H1 Antagonists Phase 3
34 Histamine Antagonists Phase 3
35
Histamine Phosphate Phase 3 51-74-1 65513
36 Serotonin 5-HT3 Receptor Antagonists Phase 3
37 Anti-Infective Agents Phase 3
38 Analgesics, Opioid Phase 3
39 Paliperidone Palmitate Phase 3
40 Anti-Bacterial Agents Phase 3
41 Narcotics Phase 3
42 Narcotic Antagonists Phase 3
43
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
44
Modafinil Approved, Investigational Phase 2 68693-11-8 4236
45
Diethylpropion Approved, Illicit Phase 1, Phase 2 90-84-6, 134-80-5 7029
46
Dextroamphetamine Approved, Illicit Phase 1, Phase 2 51-64-9 5826
47
Bupropion Approved Phase 2 34911-55-2, 34841-39-9 444
48
Ondansetron Approved Phase 2 99614-02-5 4595
49
Emtricitabine Approved, Investigational Phase 2 143491-57-0 60877
50
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057

Interventional clinical trials:

(show top 50) (show all 51)
# Name Status NCT ID Phase Drugs
1 Cognitive Correlates of Substance Abuse, Part 1 Unknown status NCT00000346 Phase 4
2 Seroquel (Quetiapine) Therapy for Schizophrenia and Schizoaffective Disorders and Comorbid Cocaine and/or Amphetamine Abuse/Dependence: A Comparative Study With Risperidone Completed NCT00208143 Phase 4 Quetiapine;Risperidone
3 An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence Unknown status NCT02541513 Phase 3 paliparidone
4 Mirtazapine as a Treatment for Co-Occurring Opioid and Amphetamine Type Stimulant Dependence (COATS) in Malaysia Unknown status NCT02541526 Phase 3 Mirtazapine;Placebo
5 An Open-label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence (COATS) Unknown status NCT02541500 Phase 3 Minocycline
6 Extended Release Naltrexone for Treating Amphetamine Dependence in Iceland Completed NCT01100853 Phase 3 VIVITROL injection and VIVITROL Placebo Injection , 24 weeks
7 Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial. Active, not recruiting NCT02774954 Phase 3
8 A Dose Ranging Study of Modafinil for Methamphetamine Dependence Unknown status NCT00630097 Phase 2 modafinil
9 Randomised Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence Unknown status NCT00123370 Phase 2 Modafinil
10 A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP104 in Healthy Adult Volunteers With Histories of Stimulant Abuse Completed NCT00248092 Phase 1, Phase 2 NRP104
11 A Double-Blind Placebo- and Active-Controlled, Single-Dose Crossover PD and PK Study to Evaluate the Safety, Tolerability and Abuse Liability of IV Administered NRP104 25 mg and 50 mg in Adult Volunteers With Histories of Stimulant Abuse Completed NCT00247572 Phase 2 NRP104
12 Tyrosine for Methamphetamine Dependence Completed NCT00000322 Phase 2
13 Bupropion for the Treatment of Methamphetamine Dependence Completed NCT00069251 Phase 2 Bupropion
14 Double-Blind, Placebo-Controlled, Dose Response Trial of Ondansetron for the Treatment of Methamphetamine Dependence. Completed NCT00040053 Phase 2 Ondansetron
15 Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM: a 6-month Randomized Controlled Trial With 3 Months of Follow-up Completed NCT01888835 Phase 2 Mirtazapine;Placebo
16 Extended-Release Naltrexone (XR-NTX, VIVITROL) for the Treatment of Actively-Using Methamphetamine-Dependent Men Who Have Sex With Men Completed NCT01449565 Phase 2 Naltrexone;Placebo
17 Biobehavioral Interventions for HIV-negative Methamphetamine-using MSM Completed NCT00856323 Phase 2 Truvada
18 Pharmacogenomics and Medication Development for Methamphetamine Dependence Completed NCT00833443 Phase 2 Bupropion
19 Cannabinoids as a New Intervention for Amphetamine Dependence: A Proof-of-concept Study Withdrawn NCT02952196 Phase 2 drug administration
20 Safety and Tolerability Study of Sublingual Lobeline Unknown status NCT00100074 Phase 1 Lobeline
21 Assessment of Interactions Between IV Methamphetamine and Aripiprazole Unknown status NCT00089440 Phase 1 Aripiprazole
22 Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between IV Methamphetamine and Oral Bupropion Unknown status NCT00040040 Phase 1 Bupropion
23 Assessment of Interactions Between IV Methamphetamine and Reserpine Unknown status NCT00267657 Phase 1 Reserpine
24 Double-Blind, Placebo-Controlled Assessment of Interactions Between Intravenous Methamphetamine and Modafinil Unknown status NCT00265278 Phase 1 Modafinil
25 Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline Unknown status NCT00033072 Phase 1 Selegiline
26 Effects of Stimulant Dependence on Human Striatal Dopamine System Unknown status NCT00000350 Phase 1
27 Abuse Liability and Human Pharmacology of Mephedrone (4-methylmethcathinone,4-MMC) Completed NCT02232789 Phase 1 Mephedrone;3,4-methylenedioxymethamphetamine;Placebo
28 Mephedrone and Alcohol Interactions After Single-dose Administration in Humans Completed NCT02294266 Phase 1 Mephedrone and alcohol;Mephedrone;Alcohol;Placebo
29 Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine) Completed NCT00895804 Phase 1 MDMA;Pindolol
30 Interactive Effects of Doxazosin and 3,4-Methylenedioxymethamphetamine (MDMA) in Healthy Subjects Completed NCT01386177 Phase 1 3,4-Methylenedioxymethamphetamine;Doxazosin;placebo
31 Pharmacological Interaction Between Reboxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): Pharmacological Effects and Pharmacokinetics Completed NCT00886886 Phase 1 MDMA;Reboxetine, 8 mg;Placebo
32 Pharmacological Interaction Between Duloxetine and 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy): Pharmacodynamics (PD) and Pharmacokinetics (PK) Completed NCT00990067 Phase 1 3,4-Methylenedioxymethamphetamine;Duloxetine;Placebo
33 Pharmacological Interaction Between Clonidine and 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) Completed NCT01136278 Phase 1 3,4-Methylenedioxymethamphetamine;Clonidine;placebo
34 A Human Laboratory Assessment of the Safety and Potential Efficacy of Varenicline in Methamphetamine-dependent Volunteers Receiving Methamphetamine Completed NCT00713479 Phase 1 Varenicline, then placebo;Placebo, then varenicline
35 Cognitive Correlates of Substance Abuse, Part 2 Unknown status NCT00000351
36 A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence Unknown status NCT01899313
37 Combination of Psychosocial Intervention and Slow Prosecutions for the Treatment of Methamphetamine Abuse/Dependence Unknown status NCT01273701
38 The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction Unknown status NCT03318081
39 Development of Virtual Reality-Based Addiction Assessment System for Synthetic Drugs Addiction Unknown status NCT02950376
40 A Double-blind, Placebo-controlled Pilot Study of Citicoline add-on Therapy in Patients With Bipolar Disorder or Major Depressive Disorder and Amphetamine Abuse or Dependence Completed NCT00377299 Citicoline;Placebo
41 Behavior Change: Reinforcement Schedule Effects Completed NCT00158197
42 The Intervention of Group Therapy: Music in Mood Problems of Female Amphetamine Use Disorder Completed NCT03221283
43 Functional Brain Imaging in Recreational Users of Ecstasy Completed NCT00254306
44 The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus Completed NCT02285556
45 The Repetitive Transcranial Magnetic Stimulation (rTMS) for Amphetamine-type Stimulants Addiction Completed NCT02713815
46 Effects of Carvedilol on the Cardiovascular and Subjective Response to MDMA (3,4-Methylenedioxymethamphetamine, "Ecstasy") Completed NCT01270672 3,4-Methylenedioxymethamphetamine;carvedilol;placebo
47 Mother vs. Child? Healthcare Worker Perceptions of Conflict Between Maternal Autonomy and Child Health When Providing Care for Pregnant Women Engaging in Problematic Substance Use Completed NCT02797990
48 Investigation of Serotonin Neurotransmission in "Ecstasy" Users Employing Combined Dexfenfluramine Challenge and Positron Emission Tomography: a Functional Probe to Assess MDMA Neurotoxicity Completed NCT01296802 dexfenfluramine
49 CEASAR (Computerized Exercise to Alter Stimulant Approach Responses) - Piloting a Novel Intervention to Improve Outcomes in Individuals Suffering From Cocaine or Methamphetamine Use Disorder: A Randomized Controlled Study Recruiting NCT03902405
50 Implementation and Effectiveness of Multidiscipline-Integrated Addiction Treatment Model Not yet recruiting NCT04203654

Search NIH Clinical Center for Amphetamine Abuse

Cochrane evidence based reviews: amphetamine-related disorders

Genetic Tests for Amphetamine Abuse

Anatomical Context for Amphetamine Abuse

MalaCards organs/tissues related to Amphetamine Abuse:

40
Brain, Cortex, Prefrontal Cortex, Heart, Lung, Thyroid, Breast

Publications for Amphetamine Abuse

Articles related to Amphetamine Abuse:

(show top 50) (show all 250)
# Title Authors PMID Year
1
An epidemic amphetamine problem: commentary on treatment of amphetamine abuse/use disorder. 61
31845158 2019
2
Treatment of amphetamine abuse/use disorder: a systematic review of a recent health concern. 61
31228128 2019
3
Wild at heart: 34-year-old male with new onset dyspnea, heart failure and history of amphetamine use; a case report. 61
31659579 2019
4
Relationship Between Lifestyle and Family Functioning Among Family Members of Amphetamine Abusers in Southeast Iran. 61
31162215 2019
5
Development of a Semimechanistic Pharmacokinetic-Pharmacodynamic Model Describing Dextroamphetamine Exposure and Striatal Dopamine Response in Rats and Nonhuman Primates following a Single Dose of Dextroamphetamine. 61
30733244 2019
6
Inhibitory control failures and blunted cortisol response to psychosocial stress in amphetamine consumers after 6 months of abstinence. 61
31007690 2019
7
Conditions and Factors Associated With Spontaneous Coronary Artery Dissection (from a National Population-Based Cohort Study). 61
30477805 2019
8
Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review. 61
31133886 2019
9
Amphetamine availability predicts amphetamine-related mental health admissions: A time series analysis. 61
29551076 2018
10
An unsuspected role for organic cation transporter 3 in the actions of amphetamine. 61
29773909 2018
11
Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats. 61
29528663 2018
12
Methamphetamine-Induced Cardiomyopathy (MACM) in a Middle-Aged Man; a Case Report. 61
29503834 2018
13
Tracing methamphetamine and amphetamine sources in wastewater and receiving waters via concentration and enantiomeric profiling. 61
28551534 2017
14
Recreational Marijuana Use and Acute Myocardial Infarction: Insights from Nationwide Inpatient Sample in the United States. 61
29312837 2017
15
[Amphetamine abuse is a possible cause of pontine haemorrhage]. 61
29084616 2017
16
Tamoxifen and amphetamine abuse: Are there therapeutic possibilities? 61
27585851 2017
17
Cardiovascular Complications of Acute Amphetamine Abuse: Cross-sectional study. 61
28417026 2017
18
[Prevalence and Therapy of Crystal Methamphetamine Dependence]. 61
28235211 2017
19
Acceleration of cardiovascular-biological age by amphetamine exposure is a power function of chronological age. 61
28243315 2017
20
Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C. 61
27647375 2016
21
A Case of Mania Presenting with Hypersexual Behavior and Gender Dysphoria that Resolved with Valproic Acid. 61
27994833 2016
22
Clinical Characteristics and Outcomes of Patients with Amphetamine-Associated Cardiomyopathy in South Auckland, New Zealand. 61
27185546 2016
23
Facial movement disorder and dopamine imaging in a patient with amphetamine abuse. 61
27502592 2016
24
PKCβ Inhibitors Attenuate Amphetamine-Stimulated Dopamine Efflux. 61
26996926 2016
25
D1 receptor-mediated inhibition of medial prefrontal cortex neurons is disrupted in adult rats exposed to amphetamine in adolescence. 61
26946269 2016
26
The prevalence and clinical features of amphetamine-induced obsessive compulsive disorder. 61
26811120 2016
27
Extended Detection of Amphetamine and Methamphetamine in Oral Fluid. 61
26402425 2016
28
Patterns of drug abuse among drug users with regular and irregular attendance for treatment as detected by comprehensive UHPLC-HR-TOF-MS. 61
26017246 2016
29
Amphetamine Abuse Related Acute Myocardial Infarction. 61
26998366 2016
30
Amphetamine sensitization in mice is sufficient to produce both manic- and depressive-related behaviors as well as changes in the functional connectivity of corticolimbic structures. 61
25959066 2015
31
[The complex of neurological symptoms of substance abuse]. 61
26829868 2015
32
Amphetamine abuse as a rare cause of recurrent LVAD pump thrombosis. 61
25545600 2015
33
Effects of anabolic-androgens on brain reward function. 61
26379484 2015
34
Gabapentin Therapy in Psychiatric Disorders: A Systematic Review. 61
26835178 2015
35
Superior Mesenteric Artery Syndrome Associated with Rapid Weight Loss Attributed to Amphetamine Abuse. 61
26351593 2015
36
Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment. 61
25479916 2015
37
[Amphetamine abuse and drug interactions]. 61
25394841 2014
38
Digital holographic microscopy discriminates sex differences in medial prefrontal cortex GABA neurons following amphetamine sensitization. 61
24999221 2014
39
c-MRI findings after crystal meth abuse. 61
25026102 2014
40
The effects of paradoxical sleep deprivation on amphetamine-induced behavioral sensitization in adult and adolescent mice. 61
24844977 2014
41
Amphetamine-related disorders in psychiatric emergency service. 61
24462022 2014
42
Factors associated with buprenorphine compared to amphetamine abuse among clients seeking treatment in Finland. 61
24560129 2014
43
Course and moderators of emotional eating in anorectic and bulimic patients: a follow-up study. 61
24854803 2014
44
Extreme Procalcitonin Elevation without Proven Bacterial Infection Related to Amphetamine Abuse. 61
24826347 2014
45
A rare case of diffuse alveolar hemorrhage following oral amphetamine intake. 61
24765773 2014
46
Negative priming in amphetamine psychosis. 61
23773294 2013
47
Androgenic anabolic steroid, cocaine and amphetamine abuse and adverse cardiovascular effects. 61
24719633 2013
48
Efficacy of psychostimulant drugs for amphetamine abuse or dependence. 61
23996457 2013
49
The influence of ionotropic and metabotropic glutamate receptor ligands on anxiety-like effect of amphetamine withdrawal in rats. 61
23623810 2013
50
An unusual case of silent acute ST-elevation myocardial infarction following amphetamine use. 61
24353688 2013

Variations for Amphetamine Abuse

Expression for Amphetamine Abuse

Search GEO for disease gene expression data for Amphetamine Abuse.

Pathways for Amphetamine Abuse

Pathways related to Amphetamine Abuse according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.47 SLC6A3 SLC18A2 DRD5 DRD4 CREB5
2 11.83 SLC6A4 SLC6A3 SLC6A2
3 11.71 SLC6A4 SLC18A2 HTR1B
4
Show member pathways
11.67 HTR1B DRD5 DRD4
5
Show member pathways
11.63 SLC6A3 SLC18A2 CREB5 ARC
6
Show member pathways
11.62 SLC6A4 SLC6A2 SLC22A3
7
Show member pathways
11.47 SLC6A4 SLC6A3 SLC6A2 SLC22A3 SLC18A2
8
Show member pathways
11.18 SLC6A4 SLC6A3 SLC6A2
9 11 SLC6A3 SLC18A2
10 10.94 SLC6A4 SLC18A2 HTR1B
11
Show member pathways
10.93 SLC6A4 SLC6A3
12 10.69 SLC6A2 SLC22A3 SLC18A2
13
Show member pathways
10.53 SLC6A4 SLC6A3 SLC6A2 SLC18A2 HTR1B DRD5

GO Terms for Amphetamine Abuse

Cellular components related to Amphetamine Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.16 SLC6A4 SLC6A3 SLC6A2 SLC22A3 SLC18A2 HTR1B
2 plasma membrane GO:0005886 10.06 SLC6A4 SLC6A3 SLC6A2 SLC22A3 SLC18A2 PRKCH
3 membrane raft GO:0045121 9.55 SLC6A4 SLC6A3 SLC6A2 CNR1 ARC
4 presynaptic membrane GO:0042734 9.54 SLC6A3 SLC6A2 CNR1
5 neuronal cell body membrane GO:0032809 9.43 SLC6A3 SLC6A2
6 dopaminergic synapse GO:0098691 9.4 SLC6A3 SLC18A2
7 integral component of plasma membrane GO:0005887 9.28 SLC6A4 SLC6A3 SLC6A2 SLC22A3 SLC18A2 HTR1B
8 serotonergic synapse GO:0099154 9.26 SLC6A4 HTR1B
9 integral component of presynaptic membrane GO:0099056 9.26 SLC6A4 SLC6A3 HTR1B CNR1

Biological processes related to Amphetamine Abuse according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.95 SLC6A4 SLC6A3 SLC6A2 SLC22A3 SLC18A2
2 response to drug GO:0042493 9.86 SLC6A4 SLC6A3 SLC6A2 HTR1B
3 response to ethanol GO:0045471 9.76 SLC6A3 HTR1B CNR1
4 chemical synaptic transmission GO:0007268 9.72 SLC6A2 SLC18A2 HTR1B DRD5 DRD4
5 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.69 HTR1B DRD4 CNR1
6 G protein-coupled serotonin receptor signaling pathway GO:0098664 9.61 HTR1B DRD4
7 negative regulation of blood pressure GO:0045776 9.61 DRD5 CNR1
8 synaptic transmission, dopaminergic GO:0001963 9.6 DRD5 DRD4
9 vasoconstriction GO:0042310 9.59 SLC6A4 HTR1B
10 neurotransmitter biosynthetic process GO:0042136 9.58 SLC6A4 SLC6A3
11 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.57 DRD4 ARC
12 neurotransmitter transport GO:0006836 9.56 SLC6A4 SLC6A3 SLC6A2 SLC18A2
13 regulation of dopamine metabolic process GO:0042053 9.54 SLC6A3 DRD4
14 response to amphetamine GO:0001975 9.54 SLC18A2 DRD5 DRD4
15 neurotransmitter reuptake GO:0098810 9.52 SLC6A4 SLC6A2
16 dopamine uptake involved in synaptic transmission GO:0051583 9.49 SLC6A3 SLC6A2
17 dopamine uptake GO:0090494 9.48 SLC6A3 SLC22A3
18 norepinephrine uptake GO:0051620 9.46 SLC6A3 SLC6A2
19 response to cocaine GO:0042220 9.46 SLC6A3 HTR1B DRD5 CNR1
20 serotonin uptake GO:0051610 9.43 SLC6A4 SLC18A2
21 norepinephrine transport GO:0015874 9.4 SLC6A3 SLC6A2
22 dopamine transport GO:0015872 9.13 SLC6A3 SLC22A3 SLC18A2
23 monoamine transport GO:0015844 9.02 SLC6A4 SLC6A3 SLC6A2 SLC22A3 SLC18A2

Molecular functions related to Amphetamine Abuse according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 symporter activity GO:0015293 9.65 SLC6A4 SLC6A3 SLC6A2
2 drug binding GO:0008144 9.56 SLC6A3 HTR1B DRD4 CNR1
3 neurotransmitter receptor activity GO:0030594 9.51 HTR1B DRD4
4 neurotransmitter:sodium symporter activity GO:0005328 9.5 SLC6A4 SLC6A3 SLC6A2
5 G protein-coupled serotonin receptor activity GO:0004993 9.49 HTR1B DRD4
6 serotonin binding GO:0051378 9.46 SLC6A4 HTR1B
7 dopamine neurotransmitter receptor activity GO:0004952 9.43 DRD5 DRD4
8 serotonin:sodium symporter activity GO:0005335 9.4 SLC6A4 SLC18A2
9 norepinephrine:sodium symporter activity GO:0005334 9.37 SLC6A3 SLC6A2
10 dopamine binding GO:0035240 9.33 SLC6A3 DRD5 DRD4
11 dopamine:sodium symporter activity GO:0005330 9.13 SLC6A3 SLC6A2 SLC22A3
12 monoamine transmembrane transporter activity GO:0008504 8.92 SLC6A4 SLC6A3 SLC6A2 SLC18A2

Sources for Amphetamine Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....